

Amendments to the Specification

Please amend the Abstract of this application as following:

--Methods ~~are disclosed~~ for the treatment and prevention of disorders and conditions using a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound are disclosed. Disorders and conditions that can be treated or prevented include such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.

Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.--